GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Debt-to-EBITDA

Incanthera (AQSE:INC) Debt-to-EBITDA : -0.16 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Incanthera's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.00 Mil. Incanthera's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.20 Mil. Incanthera's annualized EBITDA for the quarter that ended in Sep. 2023 was £-1.23 Mil. Incanthera's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Incanthera's Debt-to-EBITDA or its related term are showing as below:

AQSE:INC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.18   Med: -0.15   Max: -0.15
Current: -0.18

During the past 4 years, the highest Debt-to-EBITDA Ratio of Incanthera was -0.15. The lowest was -0.18. And the median was -0.15.

AQSE:INC's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs AQSE:INC: -0.18

Incanthera Debt-to-EBITDA Historical Data

The historical data trend for Incanthera's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Debt-to-EBITDA Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
- - - -0.15

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial - - - -0.15 -0.16

Competitive Comparison of Incanthera's Debt-to-EBITDA

For the Biotechnology subindustry, Incanthera's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incanthera's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incanthera's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Incanthera's Debt-to-EBITDA falls into.



Incanthera Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Incanthera's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.131) / -0.889
=-0.15

Incanthera's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.195) / -1.23
=-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.


Incanthera  (AQSE:INC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Incanthera Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Incanthera's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines